Cynata Therapeutics Limited

ASX:CYP.AX

0.2 (AUD) • At close September 6, 2024
Bedrijfsnaam Cynata Therapeutics Limited
Symbool CYP.AX
Munteenheid AUD
Prijs 0.2
Beurswaarde 36,135,200
Dividendpercentage 0%
52-weken bereik 0.105 - 0.345
Industrie Biotechnology
Sector Healthcare
CEO Dr. Kilian Kelly
Website https://www.cynata.com

An error occurred while fetching data.

Over Cynata Therapeutics Limited

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It

Vergelijkbare Aandelen

Patrys Limited logo

Patrys Limited

PAB.AX

0.006 AUD

Pharmaxis Ltd logo

Pharmaxis Ltd

PXS.AX

0.028 AUD

Dimerix Limited logo

Dimerix Limited

DXB.AX

0.4 AUD

Imagion Biosystems Limited logo

Imagion Biosystems Limited

IBX.AX

0.032 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)